Abstract #2088
Development of CEST MRI for the characterization of Alzheimer’s Disease
Fang Frank Yu1, Natalie M Bell1, Elizabeth M Davenport1,2, Spencer Bowen1,2, Brendan James Kelley3, Ivan Dimitrov2,4, Jochen Keupp5, and Elena Vinogradov1,2
1Radiology, University of Texas Southwestern Medical Center, Dallas, TX, United States, 2Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, 3Neurology, University of Texas Southwestern Medical Center, Dallas, TX, United States, 4Philips Healthcare, Gainseville, GA, United States, 5Philips Research, Hamburg, Germany
Synopsis
Alzheimer’s Disease (AD) is the leading cause of dementia, afflicting over 5 million Americans and 45 million people worldwide. We are developing CEST protocol for the characterization of abnormal protein accumulation and pathological molecular changes in AD. Our results indicate increased CEST in all frequency ranges, with the maximum around 2ppm. While preliminary, this data demonstrates CEST MRI is capable of clear differentiation between patients with AD and healthy individuals.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
